RAL-eve Study: Raltegravir Substitution Study

NCT ID: NCT00523237

Last Updated: 2011-11-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 14 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-10-31
• Study Completion Date: 2010-12-31

Brief Summary

The purpose of this study is to:

• Provide raltegravir to subjects with HIV and an undetectable viral load who are experiencing injection site reactions (ISR) to Enfuvirtide,
• Monitor the safety and efficacy of raltegravir, and
• Assess the change in quality of life in patients who have switched from Enfuvirtide to raltegravir

Detailed Description

We enrolled virologically suppressed HIV-1 infected patients with injection site reactions for a switch from enfuvirtide to raltegravir. At baseline, enfuvirtide was switched to raltegravir without additional changes to the antiretroviral regimen allowed. Viral load, T-cells, and toxicity were evaluated at baseline, 2, 4, 12 and 24 weeks. Adherence and injection site reactions were evaluated at baseline, 4, 12 and 24 weeks. The single-copy assay was used to measure HIV RNA levels at screening, baseline and at 12 and 24 weeks.

Conditions

HIV Infections

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

Raltegravir

400 mg Twice daily for 24 weeks

Intervention Type: DRUG

Other Intervention Names

Isentress

Eligibility Criteria

Inclusion Criteria

1. HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry.

2. ART for at least 6 months prior to study entry with a regimen that includes enfuvirtide.

3. Self-defined infusion site reaction to enfuvirtide (usually will be painful inflammatory nodules)

4. No change in ART regimen for at least 3 months prior to study entry.

5. CD4+ cell count >50/mm3 at screening (obtained within 60 days prior to study entry).

6. Documentation of HIV-1 RNA below the limit of quantification of an ultrasensitive assay

7. All HIV-1 RNA levels obtained within 6 months prior to study entry are below the limits of quantification on all tests, except as explained above in section 4.1.6 for a single detectable viral load of <50 copies but <200 copies in last 6 months.

8. Laboratory values obtained within 60 days prior to entry:

• Absolute neutrophil count (ANC) >750/mm3
• Hemoglobin >9.0 g/dL for female subjects and>10.0 g/dL for male subjects
• Platelet count >50,000/mm3
• Calculated creatinine clearance (CrCl) >30 mL/min, as estimated by the Cockcroft-Gault equation*
• AST (SGOT), ALT (SGPT), and alkaline phosphatase <5 x ULN
• Total bilirubin <2.5 x ULN. If the subject is taking an indinavir- or atazanavir-containing regimen at the time of screening, total bilirubin <5 x ULN is acceptable.

9. For females of reproductive potential will need a negative serum or urine pregnancy test within 48 hours prior to entry.

10. Men and women age >18 years.

11. Ability and willingness of subject to provide informed consent.

Exclusion Criteria

1. Unstable clinical condition, such as unstable cardiac disease, or cancer requiring ongoing chemotherapy or radiation therapy, or other medical condition which, in the opinion of the investigator, would preclude a subject from safely undergoing study procedures.

2. Breast-feeding or pregnancy.

3. An opportunistic infection within 60 days prior to entry.

4. Known allergy/sensitivity or any hypersensitivity to components of study drug(s) or their formulation.

5. Active drug or alcohol use or dependence that, in the opinion of the Protocol Director, would interfere with adherence to study requirements.

6. Receipt of a non-HIV vaccination within 30 days prior to study entry or plan for receipt of vaccination during the study.

7. Plan to change the background ART within 24 weeks after study entry.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Stanford University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Andrew R Zolopa

Role: PRINCIPAL_INVESTIGATOR

Stanford University

Locations

Stanford University School of Medicine

Stanford, California, United States

Countries

United States

References

Grant PM, Palmer S, Bendavid E, Talbot A, Slamowitz DC, Cain P, Kobayashi SS, Balamane M, Zolopa AR. Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life. J Clin Virol. 2009 Dec;46(4):305-8. doi: 10.1016/j.jcv.2009.09.025. Epub 2009 Oct 12.

Reference Type: RESULT

PMID: 19819183 (View on PubMed)

Other Identifiers

RAL-eve study

Identifier Type: -

Identifier Source: org_study_id

NCT00627939

Identifier Type: -

Identifier Source: nct_alias